Honda Autonomous Driving is the First Level-3 System from US Manufacturer

Watch out Tesla – Honda has announced their latest innovation in autonomous driving with “Sensing 360.” Honda plans to roll out this technology suite globally in 2024. Honda autonomous driving will feature assisted driving features like “Autonomous emergency braking with expanded cross-traffic, pedestrian detection capabilities, front cross-traffic alert, active lane-change assist (blind-spot monitoring), [and] lane-change collision mitigation (blind-spot assist).”

Honda autonomous driving, “Sensing 360” is meant to be a level-3 self-driving vehicle making it the only US brand past level-2. A level-3 system means it is fully auto-pilot and the driver will only need to operate when they choose to.

While other transportation giants like Ford, GM, and Mercedes offer similar technologies, it is important to remember that none of these platforms offer a truly autonomous driving experience. According to Vitaly Golomb, Partner at Drake Star Partners, these companies will continue to roll out incremental improvements, but fully autonomous driving remains decades away.

Vitaly’s Thoughts

“Honda is the latest company to announce plans for advanced driving assist. Though Tesla is known for promising full self driving for the last nine years and recently opening up its beta system publicly, legally it is still classified as a level 2 system with all responsibility firmly in the driver’s hands. Rivian, Mercedes, Ford, GM, and others already offer advanced assistive systems today that will auto steer, keep up with traffic, and in limited cases already change lanes.

In practice, we will see continued incremental improvements in these assistive systems with increasingly more automated functionality over the rest of the decade. The first fully autonomous system also exist, but they are in controlled, off road environments. On roads, we see dedicated applications like Cruise, Waymo, and Zoox coming well before true door to door autonomy in privately owned vehicles.”

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More